Introduction
A variety of cancer vaccine therapies using tumor cells modified by gene transduction of cytokines such as TNF, [1] [2] [3] [4] IFN-␥, 5 IL-2, 6 GM-CSF, 7 etc, have been performed in animal models and have showed remarkable antitumor effects in most cases. However, in experiments examining the therapeutic effects on pre-existing parental tumors, which are inoculated away from the vaccination site, very little success has been reported.
We ourselves have demonstrated that although the vaccination of TNF gene-transduced fibrosarcoma cells (Meth-A) brought about growth inhibition of parental tumors by augmenting CTL activity after being inoculated at the opposite flank of the vaccination site, the inhibition effect was limited to relatively small tumors. 2, 3 One of the mechanisms underlying such poor response of parental tumors to vaccination may be related to their intrin-of eight mice treated with 1000 U TNF, partial regression was observed in mice treated with 500 U, and a lesser yet significant regression was observed in mice treated with only 300 U. Contrarily, in the mice which had received vaccination without the TNF pretreatment, no complete regression was observed. This effect was inhibited with the anti-class I antibody or anti-CD8 antibody. Growth of a reestablished, B16 tumor was significantly suppressed with a combination of TNF preadministration and vaccination of TNF gene-modified B16. These results indicate that preadministration of low-dose TNF may be promising for enhancing vaccination effects of TNF gene-modified tumor cells. Gene Therapy (2001) 8, 499-507.
sically impaired antigenicity. Tumors established in vivo are often impaired in the expression of cell surface molecules including antigens themselves, MHC class I and II, co-stimulatory factors and adhesion molecules, and thereby escape immunological recognition by effector cells. [8] [9] [10] In clinical trials of immune gene therapy, outcomes reported so far have been discouraging most likely due to a similar escape mechanism.
When tumor cells are exposed to cytokines such as IFN-␥, TNF-␣ or IL-12, expressions of MHC class I, II and ICAM I are known to increase. 2, 4, [11] [12] [13] [14] [15] [16] [17] [18] This effect may partly explain the reduced tumorigenicity of cytokine gene transfectants, which are exposed to high levels of locally secreted cytokines through the autocrine manner.
However, when vaccination is administered far from the site of the nontransduced tumor, the tumor may not be accessible to cytokines at effective concentrations for induction of surface molecules.
In the present experiment, therefore, TNF was first systemically injected to mice pre-inoculated with a parental tumor (Meth-A or B-16) to enhance the tumors' expression of MHC class I, and then the TNF gene transduced Meth-A or B-16 cells was administered.
Although TNF is well accepted as a potent antitumor agent which evokes apoptosis and necrosis in tumors directly, because of its severely adverse effects at dosages needed to bring about direct antitumor effects, clinical application has been suspended.
Therefore, in the present study, the concentration of TNF systemically administered was reasonably low to avoid severe side-effects, but sufficient for induction of MHC class I.
The results thus obtained demonstrated a clear augmentation of the vaccination effect of gene-modified cells by preadministration of TNF.
Results
Increment of class I expression of Meth-A cells by TNF treatment in vitro MHC class I expression on Meth-A cells (M0) incubated with various concentrations of TNF for 6 h was examined ( Figure 1a ). The increase of class I expression level was detected at 5 U/ml (mean channel, 77.4), became apparent at 15 U/ml (mean channel, 90.7) and then peaked and plateaued at 25 U/ml (mean channel, 96.5).
In order to investigate the time course of class I increment, M0 cells were cultured in the presence of TNF 25 U/ml for 0.5, 1, 3, 6, 12 or 24 h (Figure 1b) . Class I expression started to increase as early as 3 h after incubation with TNF, and became more evident after 6 h.
Pharmacokinetics of TNF clearance curve in vivo Dosages below 1000 U/mouse TNF i.v. have been reported to cause no marked antitumor effects. [19] [20] [21] Therefore, in the present study, three dosages, 1000 U/ mouse, 500 U/mouse and 300 U/mouse were selected for systemic administration before vaccination. To obtain the pharmacokinetics of these dosages, each dose of TNF was injected through the tail vein of BALB/c mouse and its clearance curve in circulation was monitored (Figure 2 ). The curves of each dosage showed biphasic clearance with T1/2␣ of 2.3 and T1/2␤ of 30.5 for 1000 U, 2.1 and 28.2 for 500 U, 1.9 and 26.1 for 300 U, respectively.
Persistent expression of class I on M0 cells after short exposure of TNF in vitro Taking into account that the clearance of TNF from circulation is relatively rapid, as shown in Figure 2 , an in vitro experiment was then undertaken to confirm the persistence of MHC class I expression on tumor cells after short exposure to TNF. With clearance curves of 1000 U, 500 U and 300 U, plasma TNF concentrations were above 100 U/ml, 25 U/ml and 5 U/ml, respectively, for at least the initial 30 min. Therefore, M0 cells were incubated with 100 U/ml, 25 U/ml and 5 U/ml TNF for 30 min, washed with RPMI1640 medium three times and recultivated for various periods of time. With concentrations of 100 U/ml and 25 U/ml, the increased class I expression became evident at 3 h and persisted at least for 24 h (Figure 3 ). With concentrations of 5 U/ml, the increment, though not so remarkable, also lasted for 24 h.
Enhancement of MHC class I expression in implanted M0 by systemic administration of TNF In order to examine that class I expression is indeed enhanced in vivo by administration of TNF, 1000 U, 500 U or 300 U were injected into mice bearing the M0 tumor, and immunofluorescent localization of the class I antigen in histological sections of the tumor was analyzed ( Figure  4 ). In mice injected with 1000 U TNF, expression of class I molecules was enhanced as early as 3 h, and this enhancement persisted for more than 24 h. Similarly, in mice treated with 500 U TNF the expression of class I increased, though to a lesser degree, but also persisted for a period of over 24 h. With 300 U TNF, the expression was rather faint. The class I expression of tumors from mice vaccinated with TNF gene-transduced Meth A cells (C5) without TNF pretreatment was not enhanced, showing similar staining intensity as that of nontreated control M0 tumors. The enhancement of class I of M0 tumor of mice injected with 1000 U TNF was further confirmed by RT-PCR-analysis ( Figure 5 ). Class I mRNA, expressed as a ratio to ␤-actin mRNA, increased for 3 h after TNF injection and gradually decreased for the following 21 h.
Synergistic effect of TNF pre-administration with TNF gene modified Meth-A cells (C5) vaccination
On the basis of the above investigations, the combination effect of TNF pre-administration and TNF gene-modified Meth-A cell (C5) vaccination on M0 tumors which had been pre-inoculated at a site removed from the vaccination site was examined ( Figure 6 ). When tumor size was relatively small (5 mm in diameter), vaccination by
Figure 3 Serial changes of class I expression on tumor cells after treatment with (a) 5 U/ml, (b) 25 U/ml or (c) 100 U/ml of TNF for 30 min, and incubation for 30 min, 1, 3, 6, 12 or 24 h without TNF. Control fluorescence was obtained with the IgG antibody alone (-). Fluorescence was obtained with an anti-class I antibody (· · ·).
Gene Therapy C5 alone brought about complete regression of M0 tumor in six out of seven mice (group B), though M0 vaccination resulted in only slight growth retardation of M0 tumor (group A). In group C mice, where tumor sizes were larger (8-10 mm diameter), no regression was observed and in fact, continued to grow even after C5 vaccination. In groups D, F and H, which would not receive C5 vaccination, TNF in concentrations of 300 U, 500 U, 1000 U, respectively, were administered to the mice. On day 10, when tumors (M0) reached 8-10 mm in diameter, two mice from each group were killed, and their tumors were examined for their histology. No apparent change (leakage of RBC from vessels, etc) was observed ( Figure  7a ) and no apoptosis in Meth-A tumor treated with TNF ( Figure 7b ), as well as control tumor (Figure 7c ) was detected. Thus, when the established tumor burden is large, neither TNF gene-modified vaccination nor TNF alone were considered to be effective in bringing about appreciable therapeutic effects.
On the other hand, in group E, group G and group I, which received combinations of TNF pretreatment in dosages of 300 U, 500 U and 1000 U TNF, respectively, and C5 vaccination when tumor size was 8-10 mm diameter, a retardation of tumor growth was clearly evident. In group I, complete tumor regression in five out of eight mice and transient regression in three of eight mice was observed ( Figure 6 ).
Generation of cytotoxic T lymphocytes (CTLs) from splenocytes of mice vaccinated with TNF gene transduced Meth A (C5)
Cytotoxicity of splenocytes from C5 vaccinated mice which underwent complete regression of tumor ( Figure  6 , group I) was determined in 51 Cr assays using M0 and YAC-1 as targets (Figure 8a ). Specific cytolysis for M0 was clearly detected when C5 cells were used as stimulator cells. The specific cytolysis for M0 was also noted when M0 cells were used as stimulators, though the cytolytic activity was relatively low as compared with that of C5-stimulated cells. Lymphokine-activated killer (YAC-1) activity of C5-treated splenocytes was far lower than the killer cell activity described above. These results suggested that TNF gene transduction enhances the generation of specific cytotoxic T lymphocytes (CTLs). To characterize the phenotype of CTLs thus generated, cyto- toxicity in the presence of anti-CD8 mAb and anti-CD4 mAb was assessed. As shown in Figure 8b . Anti-CD8 mAb efficiently and dose dependently blocked the killing of C5 stimulated splenocytes (E/T = 50). No significant blocking by anti-CD4 mAb was observed.
Blocking of MHC class I antigen and depletion of lymphocyte subset with antibodies To implicate the enhanced expression of class I and tumor-specific killer cells and subsets in tumor regression, experiments using corresponding antibodies were carried out. BALB/c mice (group J, n = 6; group K, n = 5; group L, n = 5) were inoculated subcutaneously with 1 × 10 6 M0 cells in their right flanks. On day 7, group J mice were injected with anti-class I antibodies 3 h before and after the injection of TNF 1000 U followed by C5 vaccination 6 h later, and group K or group L mice were injected with anti-CD8 antibodies or anti-CD4 antibodies 12 h before the injection of TNF 1000 U followed by C5 vaccination 6 h later ( Figure 6 ).
The growth pattern of group J and group K, in contrast to that of group I, was significantly negated by the growth inhibitory effects of C5 vaccination combined with TNF. In group L, the negation effect was not apparent (Figure 6 ).
Induction of specific immunity against rechallenged tumors
To investigate the specificity of C5 vaccine-induced immunity further, six BALB/c mice which had undergone complete regression of the M0 tumor were rechallenged with M0 cells (n = 3) or with Colon 26 cells (n = 3) on day 18 following implantation of the initial M0 tumor. Colon 26 tumors grew progressively, whereas M0 tumors were completely rejected after forming a palpable tumor, indicating the induction of tumor-specific immunity ( Figure 9 ).
cells (M0 or C5) at day 7 at opposite flank (group A, group B or group C). (b) TNF 300 U pretreatment (group D) or TNF 300 U and vaccination (group E). (c) TNF 500 U pretreatment (group F) or TNF 500 U and vaccination (group G). (d) TNF 1000 U pretreatment (group H) or TNF 1000 U and vaccination (group I); or anti-class I antibody, TNF 1000 U pretreatment and vaccination (group J); or anti-CD8 antibody, TNF 1000 U pretreatment and vaccination (group K); or anti-CD4 antibody, TNF 1000 U pretreatment and vaccination (group L). Statistical evaluation of tumor volume was analyzed by
Synergistic effect of TNF pre-administration and vaccination with TNF modified B16 cells (B5) on B0 tumor To validate the applicability of this approach to a lessimmunogenic tumor, B16 tumor cells inoculated in C57BL/6 mice were treated in a similar manner. Although complete regression was not observed, a substantial reduction of tumor size was attained (Figure 10 ).
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Discussion
In the present investigation, we were able to demonstrate augmentation of the vaccination effects of TNF genemodified tumor cells on a relatively large pre-existing parental tumor by pre-administration of TNF.
Since the dosages of TNF (1000 U, 500 U, 300 U/ mouse) employed were not high enough to induce apparent necrotic change and apoptosis of the tumor ( Figure  7) , the augmentation was not ascribed to the direct antitumor activity of TNF. In addition, these dosages have been reported to cause no toxicity in mice. 22 In this study, body weight loss was not observed in any mice treated with TNF. When equivalent human dosages (300 000 U/m 2 , 150 000 U/m 2 , 90 000 U/m 2 ) deduced from those of mice are given to patients, the adverse effects would be either tolerable or controllable by cyclooxygenase inhibitors, such as indomethacin or ibuprofen. 23, 24 Thus, systemic administration of TNF at these dosages, in combination with vaccination of TNF gene-modified tumor cells, may be feasible in clinical trials. The fact that the expression of MHC class I on Meth-A cells was enhanced in vivo, as well as in vitro by TNF treatment, and anticlass I antibody abrogated both the tumoricidal effect in vitro and the vaccination effect, suggests that immunological recognition via the class I molecule induced by TNF is involved in the tumor regression, although it is possible that enhancement of class I on antigen-presenting cells is also partly involved in the tumor regression. For class I molecules to be recognized by CTL, it is necessary for the antigen peptide to be presented in the groove of the molecule. [25] [26] [27] In other words, even if we could induce high levels of class I molecules, without tumor antigens, Gene Therapy the tumor may not be regressed by CTL. Since the Meth-A tumor is known to be endowed with a tumor antigen called gp110, 28 it was reasonable to find that enhancement of class I molecules resulted in augmentation of susceptibility to CTL induced by vaccination. Regarding the subset of lymphocytes responsible for tumor-specific killing, both in vitro and in vivo experiments have defined them as mostly CD8, which is known to represent typical CTL over a wide range of tumors.
irradiated (20 Gy) C5 cells. After treatment with different concentrations of anti-CD8 mAb, anti-CD4 mAb or control IgG, the cytotoxic activity of splenocytes against 51
Cr-labeled M0 cells in each group was measured. The data represent mean ± s.d. *P Ͻ 0.01 (Student's t test).
Figure 9 Rechallenge with Meth-A and Colon 26 cells in mice vaccinated with TNF gene-transfected Meth-A cells. BALB/c mice (n =
CD4 was also found to be involved to some extent in the tumoricidal effects in vitro ( Figure 6 ). In contrast, the in vivo experiment showed almost no contribution of CD4 to tumor regression. Further characterization of this CD4 population regarding its CTL or helper cell nature remains a future task. Confirming such tumor-specific killing was the finding that rechallenged M0 cells were rejected, while Colon 26 cells were not. In addition to the class I molecule, B7 and ICAM-I, which are inducible by TNF, 13, 15, 28, 29 are also known to be essential for immunological recognition by killer cells. In fact, the abrogation of vaccination effect by anti-class I antibody was not complete, although apparent. Therefore, application of anti B-7 or anti ICAM-1 antibody may be needed for further elucidation of TNF effect. With regard to the time schedule of TNF administration and vaccination, we selected 6-h intervals on the basis of in vitro observation that class I expression of M0 was maintained at least 6-24 h after TNF treatment (Figure 1b) . However, if one considers the fact that induction of cytotoxic T cells requires a certain period of time (induction phase), the time schedule could be changed. Perhaps the interval between TNF administration and vaccination could be much shorter, or TNF administration could even be after the vaccination. Further studies may elucidate this point.
Figure 10 Therapeutic effects of TNF gene-transduced B16 (B5) vaccination with or without TNF pretreatment on pre-existing parental tumor (B0). On day 7, 2 × 10 5 B0 cells were inoculated with vaccination of B0 (group M) or TNF 1000 U (group N) or vaccination of B5 (group O) or TNF 1000 U and vaccination of B5 (group P) on day 7. Statistical evaluation of tumor volume was analyzed by
Because TNF is not the only cytokine which is capable of inducing surface molecules, as other cytokines such as IFN-␥ and IL-12 are also known to be highly potent in this respect, we may be able to combine the latter cytokines with vaccinations. Nevertheless, the fact that even B16, which is accepted as a low immunogenic tumor, was susceptible to this modality suggests its wide applicability in immunogen therapy.
Materials and methods
Cytokines
Recombinant human TNF-␣ (2.37 × 10 6 units/mg protein) and recombinant human interleukin 2 (IL-2; 4.2 × 10 4 units/mg protein) were kindly provided by Asahi Chemical Industries (Tokyo, Japan) and Takeda Pharmaceuticals (Osaka, Japan), respectively.
Cell culture
Meth-A cells (M0; 3-methylcholanthrene-induced mouse fibrosarcoma cell line, syngeneic to BALB/c mice) and B16-F10 cells (B0; highly metastatic and poorly immunogenic murine melanoma cell line, syngeneic to C57BL/6j mice) were obtained from the American Type Culture Collection (ATCC, Bethesda, MD, USA). Colon 26 cells (murine colon adenocarcinoma cell line) were obtained Gene Therapy from the Japanese Foundation for Cancer Research (Tokyo, Japan). Meth-A cells, the TNF gene-transduced Meth-A clone (C5; high-TNF producer) and Colon 26 were grown in RPMI 1640 (Gibco, Grand Island, NY, USA) supplemented with 10% heat inactivated fetal calf serum (FCS; Flow Laboratories, McLean, VA, USA), 100 U/ml penicillin, and 100 mg/ml streptomycin (Wako Pure Chemical Industries, Osaka, Japan). B16-F10 cells and the TNF gene-transduced B16 clone (B5; high-TNF producer), were grown in DMEM (Gibco, Grand Island, NY, USA) supplemented with 10% heat-inactivated FCS, 2 mm glutamine, and 1% non-essential amino acids. All the cells were maintained at 37°C in a humidified atmosphere containing 5% CO 2 .
TNF gene transduction
The TNF producer cells (A103) were established from the packaging cell ⌿CRIP transfected with supernatant of ⌿CRE that was transfected with pLJ-TNF by the calcium phosphate coprecipitation method. The pLJ-TNF was constructed by inserting a TNF fragment from pcDV-TNF into pLJ containing the NeoR gene. 2, 3 Meth-A and B16-F10 cells were incubated with the viral supernatant of A103 with a viral titer of 10 5 G418-resistant NIH3T3 colony forming unit/ml in the presence of 8 g/ml polybrene for 2 h at 37°C. Then, the infected M0 cells were washed and resuspended in RPMI 1640 medium supplemented with 10% FCS, and the infected B0 cells were washed and resuspended in DMEM supplemented with 10% FCS, 2 mm glutamine, and 1% non-essential amino acids. The infected cells were incubated with G418 (400 g/ml) for 14 days from the third day following infection. The transformants resistant to G418 were cloned by a limiting dilution method. ELISA determined TNF production of each clone. C5 and B5 were the clones that produced the highest amount of TNF (respectively, 17.8 U/ml/1 × 10 6 cells/48 h and 20.2 U/ml/1 × 10 6 cells/ 48 h).
Animals
Female BALB/c mice (8-12 weeks) and female C57BL/6 mice (8-12 weeks) were purchased from Charles River Japan Inc (Tokyo, Japan) and fed in a pathogen-free environment.
Flow cytometric analysis for murine class I antigen The 1 × 10 6 M0 cells were placed in a fresh medium 12 h before exposure to TNF concentrations of 2.5, 5, 15, 25, 35 or 45 U/ml for 6 h, or 25 U/ml of TNF for 0.5, 1, 3, 6, 12 or 24 h. In some experiments, M0 cells were treated with 100 U, 25 U or 5 U TNF only for 30 min then washed with PBS. The preparations were analyzed with FITCconjugated labeled anti-mouse class I antibody by flow cytometry using a CytronR Cell Sorter (Ortho Diagnostic Systems, Raritan, NJ, USA).
Immunohistochemistry for murine class I expression Tumor sections were perfused in 99% methanol containing 1% H 2 O 2 for 20 min at room temperature. After washing three times with PBS, the sections were incubated with 3% BSA (bovine serum albumin) for 15 min, followed by another incubation with anti-mouse class I (Caltag Laboratories, Burlingame, CA, USA) or anti-IgG control antibody (Clemente Associates, Madison, USA) for 1 h at room temperature. The sections were again Gene Therapy washed three times with PBS and incubated with FITCconjugated labeled anti-rat IgG for 10 min at room temperature and visualized on a Laser Sharp MRC-1024 Confocal Analysis System.
TUNEL assay of apoptotic cells
Apoptosis was evaluated using an apoptosis detection kit (Insitu Apoptosis Detection Kit, Takara Shuzo, Japan) with tumor sections. As a positive control, sections were pretreated with DNase I (Sigma, St Louis, MO, USA).
RT-PCR analysis for murine class I mRNA Total RNA of tumor tissue was extracted using an RNA Kit (TEL-TEST, USA). Oligo (dT)20 primers were used for cDNA synthesis using a RT-PCR high kit (Toyobo, Japan). The class I cDNA was amplified by PCR using the primers for murine MHC class I; 5′-CACGCTGCTCCTGCTGCTGGC-3′ (sense) and 5′-GCCCTCCAGGTAGGCCTTG-3′ (anti-sense). ␤-Actin primers; 5′-GTGGGCCGCTCTAGGCACCA-3′ (sense) and 5′-CGGTTGGCCTTAGGGTTCAGGGGGG-3′ (antisense) were used in all cases as internal control.
Step program involving denaturation followed by 30 cycles of amplification at 94°C for 1 min, annealing at 55°C for 1 min and polymerization at 72°C for 2 min was employed. PCR products were visualized by ethidium bromideagarose (1%) gel electrophoresis. figure (Figure 2) . After centrifugation at 1800 g for 15 min, the plasma was collected and 125 I radioactivity was measured. The plasma proteins were then precipitated by addition of trichloroacetic acid (TCA) to a final concentration of 10%. After centrifugation, the 125 I of the clear supernatant were counted. After correction for volume, the TCA-soluble (non-TNF) 125 I activity was subtracted from the plasma 125 I activity.
Implantation of tumor cells BALB/c mice were inoculated subcutaneously with 1 × 10 5 (group A (n = 7) or group B (n = 7)) or 1 × 10 6 (group C (n = 8), group D (n = 5), group E (n = 5), group F (n = 4), group G (n = 5), group H (n = 5), group I (n = 8), group J (n = 8), group K (n = 6) and group L (n = 5)) M0 cells in 100 l of RPMI 1640 medium in their right flanks. One week later, group A, group B and group C were inoculated with 1 × 10 7 irradiated M0 or C5 (5 Gy). Group D, group F and group H were injected with TNF 300 U, 500 U and 1000 U, respectively, into their tail veins on day 7. Group E, group G and group I were injected with TNF 300 U, 500 U and 1000 U, respectively, on day 7, followed by subcutaneous vaccination with 1 × 10 7 irradiated C5 (5 Gy) 6 h later. Group J, group K and group L mice were injected with TNF 1000 U on day 7, followed by subcutaneous vaccination with 1 × On day 0, 2 × 10 5 B0 cells were inoculated in C57BL/6j Mice (group M (n = 5), group N (n = 5), group O (n = 5), group P (n = 6)). The mice of group M and group O were then vaccinated with irradiated (5 Gy) B0 cells and B5 cells (1 × 10   7 ), respectively. At day 7, group N was injected with TNF 1000 U, and group P was injected with TNF 1000 U followed by subcutaneous vaccination with 1 × 10 7 irradiated B5 6 h later. The tumor volume was calculated by the following formula: V (mm 5 irradiated M0 cells in 2 ml RPMI 1640 medium in a 24-well plate, followed by addition of 50 IU/ml IL-2 on day 2 of culture. Five days after cocultivation, stimulated splenocytes were collected for evaluation of their killing activity.
Cytotoxicity assay
The 4-h 51 Cr release assay was used for the determination of killer cell cytotoxic activity as previously described. 30, 31 Briefly, M0 cells (1 × Cr were incubated in a 96-well plate with killer cells obtained from MLTC. In some experiments, C5-stimulated splenocytes were pretreated with different concentrations (1-100 g/ml) of monoclonal antibodies of CD8, CD4, or control IgG at 4°C for 1 h. After incubation for 4 h, the plate was centrifuged and the radioactivity in their supernatants was counted using a ␥-counter. Percent specific lysis was calculated as follows: % specific lysis = (mean c.p.m. from test supernatants − mean c.p.m. from supernatants of target cells alone (spontaneous release)/(mean c.p.m. after target cell lysis with lysis buffer (total release) − spontaneous release) × 100. These cells were washed twice with PBS and then used in the cytotoxicity assay.
